Veracyte, Inc. (VCYT) fair value analysis
Nasdaq · Updated 2026-10-19
VCYT price how computed
Forward Fair Value verdict
Fairly valuedVCYT is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $43.12
- Sector
- Healthcare
- 12-month range
- $30.01–$60.49
- Market cap
- $3.47B
- From 52-week high
- -28.7%
- Shares outstanding
- 80.4M
- Rank in Healthcare by discount to fair value
- #65 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Veracyte, Inc. is a diagnostics company that develops and commercializes molecular tests used to help clinicians make clinical decisions for patients with cancer and other diseases. The company operates primarily in the United States and serves healthcare providers and patients through its laboratory and testing services.
VCYT currently ranks #65 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 4 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $3.47B
- P/E (trailing)
- 22x
- Revenue (TTM)
- $562M
- Net margin
- 20.4%
- EPS (TTM)
- $1.93
- Gross margin
- 72.2%
- Debt / equity
- 0.03
- Revenue growth (3-yr avg)
- 22.3%
- Shares outstanding
- 80.4M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 53 · neutral
- 50-day average
- $43.53
- 200-day average
- $42.59
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-04 (post-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+27.6%)
2026-03 ▲ beat (+57.6%)
2025-12 ▲ beat (+35.9%)
2025-09 ▲ beat (+59.4%)
2025-06 ▲ beat (+46.7%)
2025-03 ▲ beat (+55.0%)
2024-12 ▲ beat (+40.0%)
2024-09 ▲ beat (+94.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 11 buy · 1 hold · 1 sell (13 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $58.4
- Target vs last price
- +35.4%
What our data shows for VCYT
- Our model validated 7 trailing price-to-earnings windows for VCYT, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $30.01–$60.49.
- The 14-day relative strength index sits at a neutral 53.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for VCYT
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent VCYT news
TickrTrends' derived news-sentiment signal for VCYT is currently leaning positive, computed from recent coverage.
- Director Muna Bhanji Sells 1,864 Shares of Veracyte Inc (VCYT) (gurufocus.com, 2026-10-20)
TickrTrends take: Director Muna Bhanji's sale of 1,864 shares represents insider activity worth monitoring, though individual transactions of this size do not necessarily signal broader concerns about company fundamentals. Given that TickrTrends currently assesses VCYT as fairly valued within the Healthcare sector, investors should observe whether additional insider sales accumulate or if management commentary changes regarding the company's growth prospects. The valuation context suggests the market has already priced in current expectations, making insider behavior a potentially useful signal for detecting shifts in management confidence. - Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026 (manilatimes.net, 2026-10-14)
TickrTrends take: Veracyte will announce its third quarter 2026 financial results on November 4, 2026, providing an opportunity for investors to assess whether the company's operational performance aligns with its current fairly valued status. As a Healthcare sector company, Veracyte's earnings report will be significant for determining whether revenue trends, profitability metrics, and cash flow developments support the existing valuation assessment or suggest a potential repricing. Market participants focused on valuation will likely scrutinize guidance, margin performance, and any updates to the company's competitive position within its healthcare markets. - A Look at Veracyte Inc (VCYT) After 4.1% Gain -- GF Value $39.27 vs Price $47.67 (gurufocus.com, 2026-10-06)
TickrTrends take: Veracyte Inc trades at a premium to its GF Value estimate, with the stock price approximately 21% above the derived fair value figure. TickrTrends currently rates the stock as overvalued within the Healthcare sector, suggesting that valuations may need to compress or company fundamentals may need to strengthen for the stock to align with its estimated intrinsic value. Investors focused on valuation metrics should monitor whether upcoming earnings or operational developments justify the current price premium or whether mean reversion becomes more likely.
More VCYT news
- Veracyte Inc (VCYT) Stock Down 4.0% but Still Overvalued -- GF Score: 81/100 (gurufocus.com, 2026-10-02)
- Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 (manilatimes.net, 2026-09-25)
What people are saying
Follow the VCYT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for VCYT showed mixed movement this week. The 50/200-day trend state shifted from uptrend to mixed, while the sector discount rank improved from #84 to #79 among healthcare companies. The stock remains at a fairly valued assessment based on current metrics.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for VCYT shifted this week, with the valuation verdict improving from Overvalued to Fairly valued. This change reflects a recalibration of the company's valuation metrics relative to its Healthcare sector peers. The stock now trades at levels that TickrTrends considers aligned with its fundamental characteristics.
- 2026-10-05 — VCYT's 50/200-day trend state improved from mixed to uptrend this week, indicating that the stock's shorter-term momentum has aligned with its longer-term trajectory in an upward direction. Despite this positive technical shift, TickrTrends' derived indicators continue to reflect an overvalued assessment for the healthcare sector company. The trend improvement suggests increasing bullish price action, though the valuation verdict remains unchanged.
- 2026-09-28 — VCYT's valuation metrics shifted this week, with the stock moving from a Fairly valued assessment to an Overvalued designation. The company's sector discount rank declined from number 80 to number 86, indicating a weakening position relative to other Healthcare sector stocks on valuation measures.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is VCYT stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), VCYT is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is VCYT's TickrTrends verdict?
VCYT's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does VCYT compare to other Healthcare stocks?
VCYT ranks #65 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is VCYT overbought or oversold?
VCYT's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does VCYT report earnings next?
VCYT's next earnings report is scheduled for 2026-11-04 (post-market), per the published earnings calendar.
Does VCYT usually beat earnings estimates?
Over its last 8 reported quarters VCYT beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about VCYT?
Of 13 analysts covering VCYT, 11 rate it a buy, 1 a hold and 1 a sell - buy-leaning, with a consensus price target of $58.4 (+35.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
VCYT vs A · VCYT vs AVAH · VCYT vs BVS · VCYT vs ELV · VCYT vs INMD